Biogen Makes Lifecycle Gambit In Next-Gen MS Drug Deal With Alkermes

ALKS 8700 could help Biogen extend its MS franchise beyond Tecfidera. The next-generation fumarate may have better GI tolerability and patent protection into 2033.